Analyst James Orsborne from Stifel Nicolaus maintained a Buy rating on Open Orphan Plc (HVO – Research Report) and decreased the price target to p30.00 from p35.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
James Orsborne’s rating is based on a combination of factors that highlight Open Orphan Plc’s growth potential and strategic positioning. The company recently secured a £2 million contract for hVIVO’s human metapneumovirus (hMPV) disease model, indicating strong momentum in acquiring new business. This contract, although initially small, suggests potential for more significant future projects once the model is fully validated and receives regulatory approval.
Furthermore, the global focus on hMPV due to recent outbreaks and the lack of specific treatments or vaccines enhances the market opportunity for hVIVO. The company’s successful pilot trials have demonstrated a safe and effective model, which could lead to expanded client offerings. Additionally, Orsborne anticipates revenue growth, supported by hVIVO’s core business and new contracts, while the current share price presents an attractive entry point for investors, with expectations of increasing earnings and margins in the coming years.